Company profile for Egis Pharmaceuticals PLC

PharmaCompass

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Related CompaniesRelated Companies

About

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.

CONTACT DETAILS

Click the arrow to open the dropdown

Events

Webinars & Exhibitions

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-45654.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-17043.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-53968.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-74381.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-76800.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-party-content-3618.pdf

    https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-45225.pdf

DATA COMPILATION #PharmaFlow

read-more
read-more
CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint
During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 

Impressions: 1153

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

#PharmaFlow by PHARMACOMPASS
10 Jul 2025

NEWS #PharmaBuzz

read-more
read-more

https://kun.uz/en/news/2025/05/27/hungarian-pharma-giants-may-launch-medicine-production-in-uzbekistan

PRESS RELEASE
24 Jun 2025

https://int.egis.health/a/egis-pharmaceuticals-plc-and-the-university-of-szeged-expand-their-cooperation

PRESS RELEASE
05 Mar 2025

https://int.egis.health/a/our-project-aimed-at-developing-oncological-active-ingredients-and-preparations-has-concluded-successfully

PRESS RELEASE
24 Feb 2025

https://int.egis.health/a/en-tou4g

PRESS RELEASE
05 Feb 2025

https://int.egis.health/a/egis-is-recognised-as-a-top-employer-2025-in-hungary

PRESS RELEASE
20 Jan 2025

https://int.egis.health/a/egis-pharmaceuticals-plc-expands-its-portfolio-with-a-well-known-product-line

PRESS RELEASE
16 Dec 2024

KEY PRODUCTS

read-more
read-more

TOP RANKED SUPPLIER FOR:

Sponsored Ads.
full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view

Services

Discover the service capabilities from this company

KEY SERVICES

read-more
read-more

TOP RANKED SUPPLIER FOR:

Development of Chemical Intermediates
full-view
Small Molecule API Development Services
full-view
Intermediates for Anti-Cancer APIs
full-view
Highly Potent API (HPAPI) Manufacturing
full-view

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Contact Egis Pharmaceuticals PLC and get a quotation

Egis Pharmaceuticals PLC is a supplier offers 50 products (APIs, Excipients or Intermediates).

Find a price of Promethazine Hydrochloride bulk with DMF, CEP, JDMF offered by Egis Pharmaceuticals PLC

Find a price of Allopurinol bulk with CEP, JDMF offered by Egis Pharmaceuticals PLC

Find a price of Chlorpromazine Hydrochloride bulk with CEP, JDMF offered by Egis Pharmaceuticals PLC

Find a price of Ethacrynic Acid bulk with DMF, CEP offered by Egis Pharmaceuticals PLC

Find a price of Allopurinol bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Amlodipine Besylate bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Aripiprazole bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Bisoprolol Fumarate bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Carbidopa bulk with JDMF offered by Egis Pharmaceuticals PLC

Find a price of Carvedilol bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Duloxetine Hydrochloride bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Levomepromazine Maleate bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Methyldopa bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Quetiapine Hemifumarate bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Ramipril bulk with CEP offered by Egis Pharmaceuticals PLC

Find a price of Tofisopam bulk with JDMF offered by Egis Pharmaceuticals PLC

Find a price of Abemaciclib bulk offered by Egis Pharmaceuticals PLC

Find a price of Abrocitinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Acalabrutinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Alectinib Hydrochloride bulk offered by Egis Pharmaceuticals PLC

Find a price of Avapritinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Blarcamesine bulk offered by Egis Pharmaceuticals PLC

Find a price of Carbadox bulk offered by Egis Pharmaceuticals PLC

Find a price of Clomiphene Citrate bulk offered by Egis Pharmaceuticals PLC

Find a price of Crotamiton bulk offered by Egis Pharmaceuticals PLC

Find a price of Dapagliflozin Propanediol Monohydrate bulk offered by Egis Pharmaceuticals PLC

Find a price of Deucravacitinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Donepezil bulk offered by Egis Pharmaceuticals PLC

Find a price of Empagliflozin bulk offered by Egis Pharmaceuticals PLC

Find a price of Entrectinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Etrasimod bulk offered by Egis Pharmaceuticals PLC

Find a price of Fruquintinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Ketoprofen bulk offered by Egis Pharmaceuticals PLC

Find a price of Levocetirizine Dihydrochloride bulk offered by Egis Pharmaceuticals PLC

Find a price of Methoprene bulk offered by Egis Pharmaceuticals PLC

Find a price of Nifedipine bulk offered by Egis Pharmaceuticals PLC

Find a price of Nitrendipine bulk offered by Egis Pharmaceuticals PLC

Find a price of Osimertinib Mesylate bulk offered by Egis Pharmaceuticals PLC

Find a price of Ozanimod bulk offered by Egis Pharmaceuticals PLC

Find a price of Palbociclib bulk offered by Egis Pharmaceuticals PLC

Find a price of Pimavanserin Tartrate bulk offered by Egis Pharmaceuticals PLC

Find a price of Resmetirom bulk offered by Egis Pharmaceuticals PLC

Find a price of Ribociclib bulk offered by Egis Pharmaceuticals PLC

Find a price of Rivaroxaban bulk offered by Egis Pharmaceuticals PLC

Find a price of Sacubitril-Valsartan bulk offered by Egis Pharmaceuticals PLC

Find a price of Solriamfetol Hydrochloride bulk offered by Egis Pharmaceuticals PLC

Find a price of Tofisopam bulk offered by Egis Pharmaceuticals PLC

Find a price of Troriluzole bulk offered by Egis Pharmaceuticals PLC

Find a price of Upadacitinib bulk offered by Egis Pharmaceuticals PLC

Find a price of Venetoclax bulk offered by Egis Pharmaceuticals PLC

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty